SUN-254 A Long-Term, Phase IV Study of Omnitrope®, a Recombinant Human Growth Hormone (rhGH), in Short Children Born Small for Gestational Age (SGA)

Background: Children born SGA are predisposed to metabolic abnormalities. While the therapeutic benefit of rhGH therapy in improving height is widely recognised, it can affect carbohydrate metabolism, potentially inducing diabetes. This ongoing, prospective study aims to evaluate the long-term safet...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Autores principales: Schwarz, Hans-Peter, Giemza, Tomasz, Jathanakodi, Shrihari, Zouater, Hichem, Zabransky, Markus
Formato: Artigo
Lenguaje:Inglês
Publicado: Endocrine Society 2019
Materias:
Pediatric Endocrinology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6552986/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-254
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares